<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443090</url>
  </required_header>
  <id_info>
    <org_study_id>NM-F15-202</org_study_id>
    <nct_id>NCT02443090</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men</brief_title>
  <official_title>An 8-Week Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of fispemifene in men with secondary hypogonadism and
      sexual side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2 study is a double-blind, placebo controlled, parallel arm study with a 4 week
      run-in and an 8-week treatment period. It will assess the safety and tolerability of
      fispemifene, and the effects of treatment on the sexual side effects seen in this patient
      population using PRO endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IIEF-EF (International Index of Erectile Function - erectile function domain) score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in the IIEF-EF (International Index of Erectile Function - erectile function domain) score from Randomization to Week 8</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Secondary Hypogonadism</condition>
  <condition>Sexual Dysfunction</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Fispemifene 450 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fispemifene capsules will be taken orally each morning immediately after eating a meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules will be taken orally each morning immediately after eating a meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fispemifene</intervention_name>
    <arm_group_label>Fispemifene 450 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A confirmed diagnosis of secondary hypogonadism

          -  Mild to moderate erectile dysfunction

          -  Ability to read, understand and complete diaries and questionnaires

          -  Ability to safely make sexual attempts during the course of the study

        Exclusion Criteria:

          -  Primary hypogonadism

          -  Hypogonadism as a result of surgery, trauma, tumors or radiation of the hypothalamus
             or pituitary

          -  History or current diagnosis of breast cancer, prostate cancer and/or PSA level above
             â‰¥3.5 ng/mL

          -  Poorly controlled blood pressure, type 2 diabetes, thyroid disease; sleep apnea

          -  Elevated prolactin level

          -  Hemoglobin &gt;17 g/dL or Hematocrit &gt;50%

          -  Use of transdermal or oral testosterone within 4 weeks, intramuscular testosterone
             therapy within 6 weeks, and testosterone pellets within 6 months prior to Screening
             and at any time throughout the study

          -  Use of another SERM or past participation in a trial with Fispemifene

          -  Use of medications known to alter the HPG axis

          -  Clinically significant findings on physical exam, screening labs, or other findings
             which would prevent safe participation in the study

          -  Participation in another clinical study in the last 30 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Troupin, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>NexMed (U.S.A.), Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Health Center for Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Research LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Well Pharma Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Urology Associates, LLC, dba AdvanceMed Research</name>
      <address>
        <city>Lawrence Township</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urological Institute of Northeastern New York</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruce R. GIlbert, MD, PhD, PC</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research Practice PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians' Research Options LLC</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>November 11, 2015</last_update_submitted>
  <last_update_submitted_qc>November 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>secondary hypogonadism</keyword>
  <keyword>sexual dysfunction</keyword>
  <keyword>erectile dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

